These findings suggest that IGFBP2 promotes β-catenin activity, potentially through its interaction with the Wnt co-receptor LRP6, highlighting the role of IGFBP2 in modulating the Wnt/β-catenin signaling pathway during EMT in HCC. The gene discussed is LRP6; the disease is hepatocellular carcinoma.